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Available online 3 April 2016Background: Reduced erythrocyte survival and deformability may contribute to the so-called anemia of inﬂam-
mation observed in septic patients. Erythrocyte structure and function are affected by both the membrane
lipid composition and the organization.We therefore aimed to determinewhether these parameters are affected
during systemic inﬂammation.
Methods: A sensitive matrix-assisted laser desorption and ionization time-of-ﬂight mass spectrometric method
was used to investigate the effect of plasma components of 10 patients with septic shock and of 10 healthy vol-
unteers subjected to experimental endotoxemia on erythrocyte membrane lipid composition.
Results: Incubation of erythrocytes from healthy control donors with plasma from patients with septic shock re-
sulted inmembrane phosphatidylcholine hydrolysis into lysophosphatidylcholine (LPC). Plasma fromvolunteers
undergoing experimental human endotoxemia did not induce LPC formation. The secretory phospholipase A2 IIA
concentrationwas enhanced up to 200-fold in plasma of septic patients and plasma from endotoxin-treated sub-
jects, but did not correlate with the ability of these plasmas to generate LPC. Erythrocyte phosphatidylserine ex-
posure increased up to two-fold during experimental endotoxemia.
Conclusions: Erythrocyte membrane lipid remodeling as reﬂected by LPC formation and/or PS exposure occurs
during systemic inﬂammation in a secretory phospholipase A2 IIA-independent manner.
General signiﬁcance: Sepsis-associated inﬂammation induces a lipid remodeling of the erythrocyte membrane
that is likely to affect erythrocyte function and survival, and that is not fully mimicked by experimental
endotoxemia.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Erythrocyte
Inﬂammation
Sepsis
Lipid metabolism
Lysophosphatidylcholine
Phosphatidylserine1. Introduction
In patients with inﬂammation, anemia is associated with poor pa-
tient outcome. Next to changes in iron homeostasis and defective eryth-
ropoiesis [1,2], reduced erythrocyte lifespan contributes to “anemia of
inﬂammation” [3–5]. This condition is common in patients suffering
from sepsis [6]. Erythrocyte shape, deformability, and aggregability
were shown to be altered in these patients [7,8]. Such structural and
functional changes may contribute to the microcirculatory alterationstry (286), Radboud University
etherlands.
M. Bosman).
. This is an open access article underthat are linked to untimely erythrocyte removal in the spleen [9] and
to a poor outcome [8].
Erythrocyte structure and function depend onplasmamembrane lipid
composition [10,11]. Sepsis-associated alterations in membrane lipid
composition may contribute to alterations in erythrocyte function. In-
deed, incubation of erythrocytes from healthy volunteers with plasma
of septic patients has been shown to induce phosphatidylserine (PS) ex-
posure and membrane ceramide formation [12], both with functional
consequences [10,13].
Phospholipids constitute the majority of the erythrocyte membrane
lipids, with the glycerophospholipid (GPL) phosphatidylcholine (PC)
and the sphingolipid sphingomyelin (SM) dominating the outer mem-
brane of the lipid bilayer [10,11]. Secretory phospholipase A2 (sPLA2)
and sphingomyelinase (SMase) catalyze the hydrolysis of GPLs into
lysophospholipids (LPLs) and free fatty acids, and SM into ceramide and
choline, respectively. The activity of both lipases is enhanced in thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Demographic characteristics of septic patients.
Pt Nr. Sex (M/F) Age (years) Diagnosis APACHE II Hb (mmol/L) Transfusion history
1 V 54 Pneumosepsis 28 4.9 None
2 M 68 Abdominal sepsis after intestinal ischemia 5.1 Day before blood drawing:
3 thrombocyte transfusions
3 plasma transfusions
Day of blood drawing:
2 thrombocyte transfusions
8 plasma transfusions
9 erythrocyte transfusions
3 V 81 Abdominal sepsis in ulcerative colitis 28 6.0 None
4 M 59 Infected hip prosthesis 4.9 Day before blood drawing:
1 erythrocyte transfusion
Day of blood drawing:
1 erythrocyte transfusion
5 M 75 Cholangitis 23 8.6 Day before blood drawing:
2 thrombocyte transfusions
2 plasma transfusions
Day of blood drawing:
1 thrombocyte transfusion
6 M 82 Abdominal sepsis after intestinal ischemia 23 7.5 Day before blood drawing:
3 erythrocyte transfusions
7 M 34 Pneumosepsis 14 7.8 None
8 M 84 Urosepsis 16 6.3 None
9 V 51 Pneumosepsis 27 5.9 None
10 V 65 Toxicoderma 23 6.6 None
Mean ± SD 66.3 ± 16.1 22.8 ± 5.3 6.4 ± 1.3
187S. Dinkla et al. / BBA Clinical 5 (2016) 186–192plasma of patientswith sepsis [14,15], and the lipids they generate are in-
volved in the pathology of inﬂammation [16]. In vitro, erythrocyte
deformability and survival are negatively inﬂuenced by sPLA2 and
SMase, and by the incorporation of their products into the membrane
[9,13,17,18].
The aim of the current study was to investigate the involvement of
lipase activity in the erythrocyte-related pathophysiology during sys-
temic inﬂammation in patients with sepsis and in experimental
human endotoxemia. Using sensitive matrix-assisted laser desorption
and ionization time-of-ﬂight (MALDI-TOF) mass spectrometry (MS),
we investigated the lipid composition of erythrocytes after incubation
with the plasma of patients suffering from septic shock andwith plasma
of subjects undergoing experimental endotoxemia. A mechanistic ex-
planation for the observed changes was explored by measuring plasma
sPLA2 IIA levels and erythrocyte PS exposure.2. Material and methods
2.1. Septic patients
Anticoagulated blood (4 mL) was collected from 10 septic shock pa-
tients who resided in the department of Intensive Care Medicine of the
Radboud University Medical Center, Nijmegen, the Netherlands, and
from ten healthy volunteers. Septic shock was deﬁned as having two or
more systemic inﬂammatory response syndrome criteria [19], in combi-
nationwith a proven or suspected infection and the need for vasopressor
therapy following adequate ﬂuid resuscitation. The study was carried out
in accordance with the applicable rules on review by ethics committees
and informed consent. Blood from all patients was drawn within 24 h
after starting vasopressor therapy. Plasma, erythrocytes and erythrocyte
membrane fractions were obtained by differential centrifugation.Table 2
Characteristics of healthy subjects.
Endotoxemia subjects Healthy volunteers
N 10 10
Age (years ± SD) 22.7 ± 2.8 34.7 ± 14.8
Sex (M/F) 10/0 8/22.2. Human endotoxemia trial
This study was part of a larger endotoxemia trial (clinicaltrials.gov
identiﬁer: NCT01349699) [20]. Our analyses were performed on data of
the ten placebo-LPS-treated subjects only. The trial was approved by
the local ethics committee, and carried out according to GCP standards
and the declaration of Helsinki. A detailed protocol of the human
endotoxemia trial was previously described [20]. Blood was collected
at various time points after the injection of puriﬁed endotoxin (LPS)
prepared from E. coli O:113 (Clinical Center Reference Endotoxin, Na-
tional Institute of Health (NIH), Bethesda, MD, USA) [20].
2.3. sPLA2 IIA and cytokine measurements
sPLA2 IIA concentrationswere determined by ELISA (Cayman Chem-
ical, Ann Arbor, MI, USA). Tumor necrosis factor (TNF)-α and
interleukin-6 (IL-6) were measured by Luminex (Bio-Plex cytokine
assay, Bio-Rad, Hercules, CA, USA).
2.4. Erythrocyte isolation from blood group O, Rhesus-negative donors
EDTA-anti-coagulated bloodwas collected from several blood group
O, Rhesus-negative volunteers, and erythrocytes were isolated using
Ficoll (GE Healthcare, Waukesha WI, USA) density centrifugation.
2.5. Plasma incubation
Blood group O, Rhesus-negative erythrocytes were incubated in the
plasmaof patients or healthy volunteers at 10% hematocrit in a ﬁnal vol-
ume of 500 μL, for 20 h at 37 °Cwith gentle agitation. Erythrocytes incu-
bated with calcium-containing (2.5 mM CaCl2) Ringer with or without
bee venom sPLA2 type III (Cayman Chemical, Ann Arbor, MI, USA)
served as positive and negative controls. Absorption at 415 nmwas de-
termined to assess the extent of hemolysis.
2.6. Flow cytometry
Erythrocytes were probed for PS exposure with Annexin V-FLUOS
(Roche, Basel, Switzerland). Flow cytometry was performed as de-
scribed previously [21].
188 S. Dinkla et al. / BBA Clinical 5 (2016) 186–1922.7. MALDI-TOF MS detection of membrane lipids
Erythrocytes (50 μL) were lysed and the membrane fractions were
washed. Membrane lipids were extracted and analyzed by MALDI-TOF
MS [22–26].Fig. 1. Septic patient plasma-induced LPC formation in the erythrocyte membrane. Five repre
erythrocytes from septic patients, healthy controls (A), or control donor erythrocytes incu
controls, and iii) Ringer solution (B). All peaks are labeled according to their mass-to-charge (
Also, the m/z ratios of LPC and ceramide are indicated in panel A and panel B, respectively.
sodium adducts of LPC 16:0 (m/z 496.3 and 518.3), to the combined pool of LPC 16:0 and PC
three different donors with Ringer containing 20 and 100 ng/mL sPLA2 (C). LPC formation afte
The human sPLA2 IIA concentration in all plasma samples was determined using an ELISA (E
0.22) to the observed LPC percentage (F). Means are shown; *: P b 0.05. Abbreviations: Ce
sphingomyelin.2.8. Thin layer chromatography (TLC)
Lipids were separated using high performance TLC silica gel 60
plates, lipidswere visualized andMALDImass spectrawere recorded di-
rectly from the TLC plate as described previously [26,27].sentative examples of positive-ion MALDI-TOF MS spectra of membrane lipid extracts of
bated overnight at 37 °C with i) plasma from septic patients, ii) plasma from healthy
m/z) ratios and assignments of the most prominent peaks are given directly in the ﬁgure.
The percentage of hydrolyzed PC (LPC) was determined by comparing the proton and
16:0/18:2 (m/z 758.6 and 780.6). LPC formation after incubation of erythrocytes from
r overnight incubation with plasma from 10 septic patients and 10 healthy controls (D).
). The sPLA2 IIA concentrations measured in patients did not correlate (r =−0.44, P =
r = Ceramide, LPC = lysophosphatidylcholine, PC = phosphatidylcholine and SM =
189S. Dinkla et al. / BBA Clinical 5 (2016) 186–1922.9. Statistical analysis
Differences in the percentages of total membrane lysophos-
phatidylcholine (LPC) between two groups were determined using
Fisher's exact test. A repeated measures one-way ANOVA was used in
combination with Tukey's post-test to assess changes in erythrocyte
PS exposure over time. Differences between two groups of continuous
data were determined using theMann–Whitney U test. The relation be-
tween two parameters was assessed by Pearson correlation. Reported
values are two-sided, and a P-value of b0.05 was used for statistical
signiﬁcance.
Additional details of the methods used are given in the Supplemen-
tal Information.
3. Results
3.1. Demographic characteristics
Characteristics of the septic patients are provided in Table 1, and
characteristics of the volunteers who participated in the endotoxemia
trial (trial subjects) and of the control donors that served as controls
for the septic patient group are presented in Table 2.
3.2. Enhanced LPC generation in erythrocytes incubated with septic patient
plasma
Lipid analysis of erythrocytes from patients with septic shock and
fromcontrol donors did not reveal thepresence of lysolipids such as cer-
amide and LPC (Fig. 1A). These observationsmay yield a skewed picture
due to the loss of compromised cells by lysis or phagocytosis in the cir-
culation. Therefore, incubation of erythrocyteswith plasma of septic pa-
tients was used to investigate sepsis-associated lipid remodeling in the
circulation. The number of PS-exposing erythrocytes was within the
normal range observed in vivo [21] after incubation with patient
(0.39% ± 0.11) and with control donor (0.43% ± 0.07) plasma samples.
Incubation with septic patient plasma, and to a much lesser extent with
control donor plasma, caused the formation of LPC (Fig. 1B). Ceramide
and reactive oxygen species-generated LPLs were not observed
(Fig. 1B), even though they are readily detectable by MS [28]. TheFig. 2. Erythrocyte lipid remodeling during human experimental endotoxemia-induced inﬂam
from 10 endotoxemia trial subjects just prior to (t = 0) and 8 h after (t = 8) the administra
determined using an ELISA (A). The sPLA2 IIA concentrations at t = 0 were correlated to the c
was determined by positive-ion MALDI-TOF MS, by comparing the intensities of the proton an
and PC 16:0/18:2 (m/z 758.6 and 780.6) (C). Of the same 10 trial subjects, the percentage o
FLUOS staining (D), and TNF-α (E) and IL-6 (F) plasma concentrations were assessed by Lum
SEM. In panels E and F median values are shown, and the error bars represent the inter-quartiobserved LPC percentages were within the same range as observed
after incubation with sPLA2 (Fig. 1C). LPC formation was signiﬁcantly
enhanced in erythrocytes treated with plasma from septic patients,
but not in erythrocytes treated with plasma from control donors
(Fig. 1D). The percentage of LPC in the total plasma PC pool was much
lower for the septic patients (0.63 ± 0.35, n = 3) than for the control
donors (4.91 ± 0.49, n = 3), making the incorporation of LPC from
the plasma into the erythrocyte membrane an unlikely cause of the in-
crease observed after incubation with patient plasma.
3.3. Enhanced LPC generation does not correlate with the sPLA2 IIA plasma
concentration
The enzyme sPLA2 type IIA is the only member of the sPLA2 family
that is increased in the plasma of septic patients [29]. Indeed, all our sep-
tic patients had enhanced plasma sPLA2 IIA concentrations (50.2–
1654.0 ng/mL) as compared to the control donors (1.3–9.3 ng/mL)
(Fig. 1E), corroborating earlier observations [15,29]. However, there
was no correlation between the observed degree of LPC formation and
the sPLA2 IIA concentration (Fig. 1F). Also, no correlations were ob-
served between the percentage of LPC and the sPLA2 IIA concentration
with the patient parameters sex, age, weight, length, focus of infection,
APACHE II, temperature, mean arterial pressure, heart rate, ﬂuid bal-
ance, Glasgow coma scale, PaO2, FiO2, thrombocytes, bilirubin, creati-
nine or leukocytes (data not shown).
3.4. LPC generation and sPLA2 IIA plasma concentration in human
endotoxemia
In order to overcome the heterogeneity in origin of infection, bacte-
riology and progression of sepsis [30], we investigated the effect of sep-
sis on erythrocyte lipid composition using a human endotoxemiamodel
[20]. After LPS infusion, the sPLA2 IIA concentrations increased in almost
all trial subjects (Fig. 2A). A strong correlation (r=0.89, P b 0.001) was
observed between sPLA2 IIA levels before and 8 h after LPS infusion
(Fig. 2B). Furthermore, the sPLA2 IIA concentration at t = 0 correlated
(r= 0.68, P= 0.032) with the rise in body temperature after LPS infu-
sion. However, in contrast to that of septic patients, the plasma of the
trial subjects did not induce LPC formation in erythrocytes (Fig. 2C),mation. Allogeneic erythrocytes were incubated overnight at 37 °C with plasma obtained
tion of 2 ng/kg clinical grade LPS. The sPLA2 IIA concentration in all plasma samples was
oncentrations at t = 8 (r = 0.89, P b 0.001) (B). The percentage of hydrolyzed PC (LPC)
d sodium adducts of LPC 16:0 (m/z 496.3 and 518.3) with the combined pool of LPC 16:0
f PS-exposing erythrocytes was determined by ﬂow cytometry detection of Annexin V-
inex. In panels A, C and D means are shown; *: P b 0.05; error bars in panel D represent
le range.
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(cf. Figs. 1D and 2A). This corroborates our ﬁnding that, in septic pa-
tients, sPLA2 IIA concentration is not related with the LPC formation
(Fig. 1E).
3.5. Erythrocyte PS exposure is induced during the initial phase of human
endotoxemia
In vivo, LPC is rapidly converted into lysophosphatidic acid (LPA),
whichmay induce the exposure of the removal signal PS in erythrocytes
[31]. In trial subjects, the number of PS-exposing erythrocytes increased
strongly at 6 and 8 h after LPS infusion, to return to baseline level at 24 h
(Fig. 2D). This increase in PS-exposing erythrocytes was observed after
the onset of inﬂammation, as indicated by the TNF-α and IL-6 plasmaFig. 3.Detection of lysophospholipids. Allogeneic erythrocyteswere incubated overnight at 37 °
membrane lipids were performed (A). All peaks are labeled according to theirm/z ratios. Note t
using the identical lipid extract (B) to verify the absence of LPL other than LPC. Lipid standard
caused by the presence of small amounts of hemoglobin that could not be completely remo
LPE = lysophosphatidylethanolamine, PA = phosphatidic acid, PC = phosphatidylcholine, P
PL = phospholipid, PS = phosphatidylserine and SM= sphingomyelin.levels (Fig. 2E, F). There was a strong positive correlation (r = 0.91,
P = 0.002) between erythrocyte PS exposure before and at 6 h after
LPS infusion.3.6. The observed lipase activity selectively targets PC in the erythrocyte
sPLA2 phospholipases may not only hydrolyze PC, but also other
glycerophospholipids such as PS and phosphatidylethanolamine (PE)
[32]. Incubation of control donor erythrocytes with septic patient plas-
ma generated high levels of LPC, but no other LPLs such as lysoPE
(LPE), lysoPS, or lysophosphatidylinositol (Fig. 3A, B). Also, incubation
in Ringer that had been spikedwith recombinant sPLA2 did not generate
any LPLs other than LPC (data not shown). Most likely the plasmaCwith plasma of a septic patient. Both positive and negative-ionMALDI-TOFMS of isolated
hat there are intense signals of LPC, but no signals of other LPL species. TLC was performed
s were included to delineate the different lipid species. The pale white band in the TLC is
ved during the extraction process [33]. Abbreviations: LPC = lysophosphatidylcholine,
E = phosphatidylethanolamine, PG = phosphatidylglycerol, PI = phosphatidylinositol,
191S. Dinkla et al. / BBA Clinical 5 (2016) 186–192phospholipases are unable to attack other phospholipids in situ because
of their location in the inner leaﬂet of the erythrocyte membrane.
4. Discussion
sPLA2 phospholipases are the principal catalysts of the hydrolysis of
GPLs into LPLs and fatty acids, while SMases catalyze the hydrolysis of
SM into ceramide and phosphorylcholine. Both activities are enhanced
in patients with severe sepsis [14,15], and LPLs and ceramide have
been shown to play a role in the pathology of various inﬂammatory dis-
eases [16]. sPLA2 has attracted attention as a therapeutic target in ath-
erosclerosis [32,34]. Here, we report that the plasma of patients with
severe sepsis triggers erythrocyte membrane lipid remodeling, as
shown by enhanced LPC formation. This LPC formation was similar to
that observed after incubation with sPLA2 (Fig. 1). sPLA2 IIA is the
only sPLA2 family member of which the secretion is signiﬁcantly pro-
moted during sepsis [29]. Indeed, the sPLA2 IIA concentration was
strongly enhanced in our septic patient plasma samples. The lack of a
statistically signiﬁcant correlation between sPLA2 concentration and
LPC formation is likely due to the involvement of other sPLA2 phospho-
lipases [29]. Interestingly, we did not detect an increase in LPC genera-
tion using the plasma of subjects undergoing experimentally induced
endotoxemia, even though inﬂammation and a subsequent rise in plas-
ma sPLA2 IIA were observed. Thus, experimentally-induced acute
endotoxemiamay constitute a usefulmodel for several aspects of sepsis,
but does not fully mimic the effects of sepsis on erythrocytes. This could
be due to the human endotoxemia model mimicking only the initial
phase of septic shock [20]. The absence of LPC formation in the
endotoxemia model suggests that additional factors, or the exposure
of PS, direct sPLA2 IIA towards compromised erythrocytes.
sPLA2 IIA has been implicated in the activation of the inﬂammatory
processes responsible for multiple organ failure in sepsis [30,35], and
its plasma level correlated with the rate of mortality [15,36]. In the
human endotoxemia trial subjects, we noticed that sPLA2 IIA status at
baseline was predictive for the sPLA2 IIA response upon LPS infusion.
This suggests that there is a pre-existing, inter-individual variability in
the sPLA2 IIA response to systemic inﬂammation.
Our MS method enables both speciﬁc and sensitive detection of dif-
ferent ceramide species in membrane lipid preparations [37]. However,
and in contrast to earlier ﬁndings [12], we did not observe ceramide
after erythrocyte incubationwith septic patient plasma. Aswe could de-
tect ceramide after sphingomyelinase treatment in vitro [13] this dis-
crepancy may be caused by patient heterogeneity in the stage and
cause of sepsis.
The absence of LPLs other than LPCmay be due to the inability of the
responsible plasma lipases to attack their substrate GPLs, since the latter
primarily reside in the inner leaﬂet of the plasma membrane [10,11].
LPC acts as a substrate for lysophospholipase D and LPC acyltransferase,
to produce the pro-inﬂammatory lipid mediators LPA and platelet-
activating factor [38]. Enhanced activity of these enzymesmight explain
why LPC levels are reduced in the plasma of septic patients [39].
We observed a small increase in the percentage of PS-exposing
erythrocytes in the trial subjects after LPS infusion. Since PS-exposing
erythrocytes are rapidly removed from the circulation, the increase in
PS-exposing erythrocytes observed in endotoxemia subjects presum-
ably does not represent the actual number of erythrocytes that expose
PS after LPS infusion. In addition, signiﬁcant LPC build-up in the erythro-
cyte membrane can induce hemolysis [18,40], altermorphology, induce
microparticle release, and reducedeformability leading to splenic reten-
tion ex vivo [9]. Both the removal and metabolism hypotheses may ex-
plain our inability to detect LPC in the erythrocytes from the septic
patients. PS exposure and PC hydrolysis in the erythrocyte membrane
may contribute to the reduced erythrocyte lifespan in “anemia of in-
ﬂammation” [3–5]. Thismight also affect erythrocyte transfusion in sep-
tic patients, as blood bank erythrocytes are prone to expose PS [41]. We
found that, in trial subjects, erythrocyte PS exposure prior to LPSinfusion was predictive for the extent of erythrocyte PS exposure
upon LPS-induced inﬂammation. This is in line with our previous ﬁnd-
ing that PS exposure on stored erythrocytes predicts their extent of PS
exposure after the application of osmotic stress [21]. Therefore, deter-
mination of the PS exposure in erythrocyte concentrates might allow
the selection of products for the transfusion of septic patients. Since
blood bank erythrocytes were also found to be more susceptible for
SMase activity, it would be interesting to assess whether this also ap-
plies to sPLA2s [13].
5. Conclusions
We here provide evidence for erythrocyte membrane lipid remodel-
ing during systemic inﬂammation, as illustrated by enhanced LPC forma-
tion and PS exposure during sepsis. The enhanced LPC formation in
erythrocytes could not be attributed to sPLA2 IIA alone, and was not ob-
served in experimentally induced endotoxemia. As membrane lipid re-
modeling affects erythrocyte integrity, it is necessary to focus future
research on elucidating the identity of the phospholipase(s) responsible,
including erythrocyte-associated forms [42,43]. Comparing the
endotoxemia model with septic patients would be helpful in short-
listing relevant candidates.
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